FRANKFURT, March 20 (Reuters) - Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...

Novartis will acquire a breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, boosting ...

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...

Novartis has announced its acquisition of the promising breast cancer drug candidate SNV4818 from Synnovation Therapeutics for an initial payment of $2 billion, with an additional $1 billion ...

SNV4818 is an oral drug and is presently being assessed in an ongoing Phase I/II trial for breast cancer.

Novartis (NOVN) announces acquisition of experimental breast cancer drug SNV4818 for up to $3B. Stock dipped 0.94% on the news. Deal closes H1 2026.

Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a ...

Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI ...

Reflecting the pharmaceutical company's investment and focus on China, Novartis grew by 8 percent in the China market last ...

FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 ...